Filing excerpt
This action is separate from the Company’s March 12, 2026 voluntary Medical Device Correction.
sec.gov/Archives/edgar/data/1145197/000114519726000132/podd-20260526.htmRead the full source
Insulet8-K: Internal control weakness
Insulet reveals second manufacturing control failure at its Acton, MA facility in 2026.
What happened
A second medical device correction related to the same type of manufacturing issue ('cannula handling') indicates a systemic weakness in quality control.
Source
Other signals in this filing (4)
- Product liabilityInsulet to incur up to $50M in 2026 for second Omnipod medical device correction.Product liability
- Material contractInsulet to incur up to $50M in costs from medical device correction due to manufacturing issue.Material contract
- Quality issueInsulet to spend up to $50M on medical device correction for Omnipod quality issue.Quality issue
- Manufacturing issueInsulet faces recurring manufacturing process failure at its Acton, MA facility.Manufacturing issue
Extracted by Autobound
From the Signal API record- Signal
- 8-K: Internal control weakness
What this signalsFilings often name leadership changes, deals and spending plans.
- Form
- 8-K
- Fiscal year end
- 05/26
- Filed
- May 26, 2026
More from Insulet
- PatentsINSULET CORPORATION's patent output is accelerating: 64 grants in the past year, 10 in the past 30 days.Patents
- 8-KInsulet refinances $475M loan and increases revolving credit facility by $250M to $750M.8-K
- GlassdoorCompany revenue growth challenged by competitors and cost-cutting layoffsGlassdoor
- In developmentInsulet Reports Second-Quarter Revenue Growth as Full-Year U.S. Omnipod Outlook Is LoweredIn development
- LaunchInsulet Partners with Calm to Deliver Mental Health Tools for Diabetes CareLaunch
- 10-QCapEx up 84% to $56.8M for new Costa Rica plant and manufacturing expansion.10-Q
More 8-K signals at other companies
- SEC 8-K4D Molecular Therapeutics, Inc.4D Molecular Therapeutics initiates Phase 3 trial directly challenging competitor drug aflibercept.SEC 8-K
- SEC 8-KAdeia Inc.Adeia Inc. appoints new CEO Dipti Vachani, effective October 12, 2026, replacing outgoing CEO Paul E. Davis.SEC 8-K
- SEC 8-KAdicet Bio, Inc.Adicet Bio launching pivotal clinical trial in Q4 2026 after positive Phase 1 data for Prula-cel.SEC 8-K
The full record
From the Signal API recordDetails
- CIK
- 1145197
- Accession number
- 0001145197-26-000132
- Timeframe
- Immediate
- Filing year
- 2026
- Why it matters
- Compliance monitoring needed
- Signal category
- Risk
Topics and mentions
Regions named
- Acton, Massachusetts
Extraction
- Confidence
- High
- Relevance
- 90%
- Sentiment
- Negative
- Detected
- Jun 2, 2026
- signal_type
sec-8k- signal_subtype
internalControlWeakness
Use this data
Get every 8-K signal for Insulet and the companies you sell to, in the tools you already use.
Ask Claude about it
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Insulet this week?”
Send it to your own tools
The Signal API returns 8-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Try it free
Sign up and spend your free credits on the companies you sell to.
Start Free1,000 free credits
The API returns more than this page shows
This page shows a preview. The full sec-8k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the API
Signal
signal_nameValue in the APIassociationValue in the API
Start Free1,000 free creditsUse it in Claude via MCP
Show the full JSONHide the full JSONThe record on this page and the API request
GET /v1/signals/0f94f5af-cfd2-43a9-97d5-2c1a28b1049e returns this record as JSON. POST /v1/companies/enrich returns every signal for insulet.com.
{
"signal_id": "0f94f5af-cfd2-43a9-97d5-2c1a28b1049e",
"signal_type": "sec-8k",
"signal_subtype": "internalControlWeakness",
"detected_at": "2026-06-02T08:18:23.283+00:00",
"company": {
"name": "Insulet",
"domain": "insulet.com"
},
"data": {
"detail": "A second medical device correction related to the same type of manufacturing issue ('cannula handling') indicates a systemic weakness in quality control. The recurrence suggests existing systems and processes are insufficient, creating an opportunity for vendors of Quality Management Systems (QMS) and manufacturing process controls.",
"metrics": {
"timeframe": "immediate"
},
"summary": "Insulet reveals second manufacturing control failure at its Acton, MA facility in 2026.",
"excerpts": "This action is separate from the Company’s March 12, 2026 voluntary Medical Device Correction.",
"relevance": 0.9,
"sentiment": "negative",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/1145197/000114519726000132/podd-20260526.htm",
"filing_date": "2026-05-26",
"filing_year": 2026,
"fiscal_year_end": "05/26",
"sales_relevance": "Compliance monitoring needed",
"signal_category": "risk",
"regions_mentioned": [
"Acton, Massachusetts"
]
}
}
curl https://signals.autobound.ai/v1/signals/0f94f5af-cfd2-43a9-97d5-2c1a28b1049e \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"insulet.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.